enCAGE Therapy Clinical Study
A clinical study was completed using the current device to ablate prostate tissue in 20 patients at University College London. Dr. Mark Emberton, Dr. Clement Orczyk. The study was published in The Journal of Urology which made the following editorial comment.
“Coil RFA with the enCAGE device is a unique option for focal prostate ablation. With transperineal insertion, and ablation limited to the coil cage, treatments can be applied to both anterior and posterior lesions with minimal chance of ablating nearby vital structures.
In this series of 20 men with intermediate risk prostate cancer, no grade 3-5 adverse events were reported, and 15 men had complete absence of any cancer at the 6-month biopsy. This is impressive considering that it was the first of its kind experience and post-treatment biopsy was mandated and thorough, with a median of 6 cores from the treatment site, which is beyond the approach of most focal therapy series. The success may in large part be due to the ingenious approach of adding extra needles to pull the energy outside the coil…”
Prostate Cancer Statistics
1 out of 7 men will be diagnosed
3.1M Living with Prostate Cancer
268K New Cases/year
34K deaths annually
$5-8B/Year costs to Medicare